Medicalgorithmics has received a CE certificate allowing the PocketECG IV system together with software based on artificial intelligence to be used in the European Union markets. Obtaining the CE certificate means that the PocketECG IV arrhythmia diagnostics platform developed by Medicalgorithmics meets the quality and safety requirements of the EU Medical Devices Regulation (MDR), the company announced.
“The CE certification opens the way for us to sell PocketECG IV in the European Union and in non-EU markets that recognize the CE marking. Recently, PocketECG IV was approved for use in Canada, which is our second most important market after the USA. We are working on allowing our platform to be sold in other markets. PocketECG IV is compatible with LTE technology and meets the requirements for ECG data transmission for years ahead, which increases the attractiveness of our solution for medical facilities,” said Jarosław Jerzakowski, Member of the Management Board for Commercial Affairs at Medicalgorithmics, quoted in the release.
PocketECG IV is a technologically advanced platform for arrhythmia diagnostics. The fourth generation makes it possible to connect the PocketECG device over the LTE band, ensuring even more efficient transmission of a continuous ECG signal.
“Since the first version of PocketECG, we have focused on real-time transmission of the entire recorded ECG signal. By adding proprietary AI algorithms that analyze the recorded signal in real time, we have created a unique system over the years that provides the doctor with current information about the condition of the monitored patient. Our technology offers the highest quality analysis and gives doctors flexibility in choosing the time of patient monitoring,” said Przemysław Tadla, board member for technology at Medicalgorithmics.
Medicalgorithmics is a high-tech company present on the market since 2005, operating in the field of non-invasive medical devices. The Group strives to become a leading provider of system and algorithmic solutions in cardiological diagnostics, in particular in the field of ECG signal analysis. The company operates in, among others, the USA and Asia. In 2014, the company moved to the main market of the Warsaw Stock Exchange from NewConnect, where it had been listed since 2011. It is included in the sWIG80 index.